2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementAdjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer
Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerLonger OSAdjuvant EBRTThyroid cancerAdjuvant external beam radiotherapyNational Cancer DatabaseExternal beam radiotherapyConcurrent chemoradiationConcurrent chemotherapyImproved survivalMedian ageCancer DatabaseRetrospective analysisBeam radiotherapyEBRTChemotherapyPatientsCancerUVAChemoradiationResectionRadiotherapy
2018
Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States
Bledsoe T, Park H, Rutter C, Aneja S, Nguyen PL, Yu J. Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal Of Clinical Oncology 2018, 41: 1062-1068. PMID: 29521648, DOI: 10.1097/coc.0000000000000423.Peer-Reviewed Original ResearchTreatment modality selectionInsurance statusTreatment modalitiesProstate cancerPrivate insuranceProstate cancer treatment modalitiesMultivariable logistic regression analysisInvasive surgeryModality selectionCancer-directed treatmentD'Amico risk classificationTreatment modality choiceNational Cancer DatabaseLocalized prostate cancerPatient insurance statusExternal beam radiotherapyLogistic regression analysisHealth insurance statusStrongest predictorMen ages 18Cancer treatment modalitiesClinical factorsMultivariable analysisActive surveillanceCancer Database